But while thousands of clinical
trials on immunotherapy drugs, of which many are predicted to fail, are springing up, the depth of information on
neoantigen vaccines is much shallower: Just two studies on
neoantigen vaccines for melanoma, recently profiled in Nature, were completed last year in Boston and Germany.
Meanwhile, several biotech companies are launching
trials combining
neoantigen vaccines and checkpoint inhibitors for various cancers, including Neon Therapeutics in Cambridge, which Wu and Hacohen co-founded.